



Australian Government
Department of Health

COMMUNICABLE DISEASES INTELLIGENCE

2018 Volume 42
PII:S2209-6051(18)00017-9

Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2015

Jan M Bell, Thomas Gottlieb, Denise A Daley and Geoffrey W Coombs
for the Australian Group on Antimicrobial Resistance

COMMUNICABLE DISEASES INTELLIGENCE

© Commonwealth of Australia 2018

ISSN: 2209-6051 (Online)

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to copyright@health.gov.au.

Communicable Diseases Intelligence aims to disseminate information on the epidemiology and control of communicable diseases in Australia. Communicable Diseases Intelligence invites contributions dealing with any aspect of communicable disease epidemiology, surveillance or prevention and control in Australia. Submissions can be in the form of original articles, short reports, surveillance summaries, reviews or correspondence. Instructions for authors can be found in Commun Dis Intell 2016;40(1):E189–E193.

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.

<http://www.health.gov.au/cdna>

Editor

Cindy Toms

Deputy Editor

Phil Wright

Editorial and Production Staff

Leroy Trapani, Kasra Yousefi

Editorial Advisory Board

Peter McIntyre (Chair), David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk

Website

<http://www.health.gov.au/cdi>

Contacts

Communicable Diseases Intelligence is produced by:
Health Protection Policy Branch
Office of Health Protection
Australian Government Department of Health
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Email: cdi.editor@health.gov.au

This journal is indexed by Index Medicus and Medline.

Disclaimer

Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

Submit an Article

You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>. Further enquiries should be directed to: cdi.editor@health.gov.au.

Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2015

Jan M Bell, Thomas Gottlieb, Denise A Daley and Geoffrey W Coombs

Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2015 survey was the third year to focus on blood stream infections, and included Enterobacteriaceae, *Pseudomonas aeruginosa* and *Acinetobacter* species.

Seven thousand three hundred and thirty species, comprising Enterobacteriaceae (6,567, 89.6%), *P. aeruginosa* (660, 9.0%) and *Acinetobacter* species (103, 1.4%), were tested using commercial automated methods (Vitek® 2, BioMérieux; Phoenix™, BD) and results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2016). Of the key resistances, non-susceptibility to the third-generation cephalosporin, ceftriaxone, was found in 10.6%/10.6% of *E. coli* (CLSI/EUCAST criteria) and 5.9%/5.9% of *Klebsiella pneumoniae*, and 8.4%/8.4% *K. oxytoca*. Non-susceptibility rates to ciprofloxacin were 12.6%/13.6% for *E. coli*, 3.9%/7.2% for *K. pneumoniae*, 0.4%/0.4% for *K. oxytoca*, 3.4%/4.0% for *Enterobacter cloacae*, and 6.3%/6.5% for *Pseudomonas aeruginosa*. Resistance rates to piperacillin-tazobactam were 2.8%/6.3%, 3.5%/6.4%, 8.9%/10.2%, 15.9%/20.6%, and 7.1%/13.9% for the same four species respectively. Twenty-two isolates were shown to harbour a carbapenemase gene, 14 *bla*_{IMP}, four *bla*_{OXA-48}, one *bla*_{KPC}, one *bla*_{GES}, one *bla*_{NDM+OXA-48}, and one *bla*_{IMP+VIM}.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antibiotic resistance; bacteraemia; Gram-negative; *Escherichia coli*; Enterobacter; Klebsiella

Introduction

Emerging resistance in common pathogenic members of the Enterobacteriaceae is a worldwide phenomenon, and presents therapeutic problems for practitioners in both the community and in hospital practice. The Australian Group on Antimicrobial Resistance (AGAR) commenced surveillance of the key Gram-negative pathogens, *Escherichia coli* and *Klebsiella* species in 1992. Surveys have been conducted biennially until 2008 when annual

surveys commenced alternating between community- and hospital-onset infections (<http://www.agargroup.org/surveys>). In 2004, another genus of Gram-negative pathogens in which resistance can be of clinical importance, *Enterobacter* species, was added. *E. coli* is the most common cause of community-onset urinary tract infection, while *Klebsiella* species are less common but are known to harbour important resistances. *Enterobacter* species are less common in the community, but of high importance due to intrinsic resistance to first-line

antimicrobials used in the community. Taken together, the three groups of species surveyed are considered to be valuable sentinels for multi-resistance and emerging resistance in enteric Gram-negative bacilli. In 2013, AGAR commenced the Enterobacteriaceae Sepsis Outcome Programme (EnSOP) which focused on the collection of resistance and some demographic data on all isolates prospectively from patients with bacteraemia. In 2015, *Pseudomonas aeruginosa* and *Acinetobacter* species were added, and the program name was altered to GNSOP to reflect the additional species surveyed.

Resistances of particular interest include resistance to β -lactams due to β -lactamases, especially extended-spectrum β -lactamases, which inactivate the third-generation cephalosporins that are normally considered reserve antimicrobials. Other resistances of interest are to agents important for treatment of these serious infections, such as gentamicin; and resistance to reserve agents such as ciprofloxacin, meropenem and colistin.

The objectives of the 2015 surveillance program were to:

1. monitor resistance in Enterobacteriaceae, *P. aeruginosa* and *Acinetobacter* species isolated from blood cultures taken from patients presenting to the hospital or already in hospital;
2. examine the extent of co-resistance and multidrug resistance in the major species;
3. detect emerging resistance to newer last-line agents such as carbapenems; and
4. characterise the molecular basis of resistance to third-generation cephalosporins, quinolones, amikacin and carbapenems.

Methods

Study Design

From 1st January to 31st December 2015, 31 laboratories across Australia collected either all or up to 200 isolates from different patient episodes of bacteraemia.

Species identification

Isolates were identified using the routine method for each institution; Vitek[®], Phoenix[™] Automated Microbiology System, or where available mass spectrometry (MALDI-TOF).

Susceptibility testing

Testing was performed by two commercial semi-automated methods, Vitek[®] 2 (BioMérieux) or Phoenix[™] (BD), which are calibrated to the ISO reference standard method of broth microdilution. Commercially available Vitek[®] AST-N246 and AST-N247, or Phoenix[™] NMIC-203 cards were utilized by all participants throughout the survey period. The CLSI M100¹ and EUCAST v5.0² breakpoints from January 2016 have been employed in the analysis. For analysis of cefazolin, breakpoints of ≤ 4 for susceptible, ≥ 8 for resistant were applied due to the restricted minimum inhibitory concentration (MIC) range available on the commercial cards, recognising that the January 2016 breakpoint is actually ≤ 2 mg/L for susceptible isolates.

Multidrug resistance

For this survey, multidrug resistance was defined as acquired resistance to more than three antimicrobial classes. For each species, antimicrobials were excluded from the count if they were affected by intrinsic resistance mechanisms.

Molecular confirmation of resistances

E. coli and *Klebsiella* isolates with ceftazidime or ceftriaxone MIC > 1 mg/L, or cefoxitin MIC > 8 mg/L; *Enterobacter* spp. with cefepime MIC > 1 mg/L; all isolates with ciprofloxacin

MIC > 0.25 mg/L; all isolates with meropenem MIC > 0.25 mg/L; all isolates with amikacin MIC > 32 mg/L, and all isolates with colistin MIC > 2 mg/L were referred to a central laboratory (SA Pathology) for molecular confirmation of resistance.

All referred isolates were screened for the presence of the *bla*_{TEM} and *bla*_{SHV} genes using a real-time polymerase chain reaction (PCR) platform (LC-480) and published primers.^{3,4} A multiplex real-time TaqMan PCR was used to detect CTX-M-type genes.⁵ Isolates were probed for plasmid-borne AmpC enzymes using the method described by Pérez-Pérez and Hanson⁶, and subjected to molecular tests for Metallo-Beta-Lactamase (MBL) (*bla*_{VIM}, *bla*_{IMP} and *bla*_{NDM}), *bla*_{KPC}, and *bla*_{OXA-48-like} genes using real-time PCR.^{7,8} Known plasmid mediated quinolone resistance (PMQR) mechanisms (Qnr, efflux [*qepA*, *oqxAB*]; *aac*(6')-Ib-cr) were examined by PCR on all referred isolates with

ciprofloxacin MIC >0.25 mg/L using published methods.^{9,10} All *E. coli* were examined for presence of the O25b-ST131 clone and its *H30*- and *H30*-Rx subclones.¹¹⁻¹³

Results

The species isolated, and the numbers of each are listed in Table 1. Enterobacteriaceae accounted for 89.6%, followed by *P. aeruginosa* (9.0%) and *Acinetobacter* species (1.4%). Of the Enterobacteriaceae, three genera - *Escherichia* (61.0%), *Klebsiella* (18.5%) and *Enterobacter* (7.4%) - contributed 86.9% of all isolates. Major resistances and non-susceptibilities for the top six ranked species are listed in Table 2. Non-susceptibility, (which includes both intermediately resistant and resistant strains), has been included for some agents because these figures provide information about important emerging acquired resistances. Multiple acquired resistances by species are shown in Table 3. Multidrug resistance was detected in 20.0% of *Escherichia coli* isolates, 8.6% of *Klebsiella pneumoniae*, and 15.2% of *Enterobacter cloacae*. A more detailed breakdown of resistances and non-susceptibilities by state and territory is provided in the online report from the group (<http://www.agargroup.org/surveys>).

Escherichia coli

Moderately high levels of resistance to ampicillin (and therefore amoxycillin) were maintained (53.1%/55.1%, CLSI/EUCAST criteria), with lower rates for amoxycillin-clavulanate (13.7%/- intermediate, 8.7%/- resistant). Non-susceptibility to third-generation cephalosporins was low ceftriaxone 10.6%/10.6%, ceftazidime 6.1%/9.9%). Moderate levels of resistance were detected to cefazolin (21.8%/21.8%) and trimethoprim (31.0%/31.4%). Ciprofloxacin non-susceptibility was found in 12.6%/13.6% of *E. coli* isolates. Resistance to gentamicin (7.8%/7.9%), piperacillin-tazobactam (2.8%/6.3%), cefepime (3.7%/4.8%) were low. Four isolates had elevated meropenem MICs (≥ 0.5 mg/L). For the extended-spectrum β -lactamase (ESBL)-

Table 1. Number and proportion of species isolated, blood cultures, 2015

Species	Total	
<i>Escherichia coli</i>	4,006	54.7%
<i>Klebsiella pneumoniae</i>	977	13.3%
<i>Pseudomonas aeruginosa</i>	658	9.0%
<i>Enterobacter cloacae</i> complex	326	4.4%
<i>Klebsiella oxytoca</i>	238	3.2%
<i>Proteus mirabilis</i>	223	3.0%
<i>Serratia marcescens</i>	189	2.6%
<i>Enterobacter aerogenes</i>	131	1.8%
<i>Salmonella</i> species (non-typhoidal)	115	1.6%
<i>Morganella morganii</i>	79	1.1%
<i>Acinetobacter baumannii</i> complex	59	0.8%
<i>Citrobacter koseri</i>	55	0.8%
<i>Citrobacter freundii</i>	45	0.6%
<i>Salmonella</i> species (typhoidal)	26	0.4%
<i>Acinetobacter</i> species	20	0.3%
<i>Pantoea agglomerans</i>	13	0.2%
<i>Enterobacter</i> species	12	0.2%
<i>Raoultella ornithinolytica</i>	12	0.2%
<i>Providencia rettgeri</i>	11	0.2%
<i>Proteus vulgaris</i>	11	0.2%
Other species (total n=40)	124	1.7%
Total	7,330	

Table 2. Proportion non-susceptible and resistant (CLSI and EUCAST) to antimicrobial agents for the top six ranked species, blood cultures, 2015

Antimicrobial	Category*	E. coli (%)		K. pneumoniae (%)		P. aeruginosa (%)		E. cloacae (%)		K. oxytoca (%)		P. mirabilis (%)	
		CLSI	EUCAST	CLSI	EUCAST	CLSI	EUCAST	CLSI	EUCAST	CLSI	EUCAST	CLSI	EUCAST
Ampicillin	I	2.1	-	+	+			+	+	+	+	0.0	-
	R	53.1	55.1	+	+			+	+	+	+	17.1	17.1
Amoxycillin/clavulanate †	I	13.7	-	4.8	-			+	+	4.2	-	8.6	-
	R	8.7	-	4.2	-			+	+	7.6	-	1.8	-
Piperacillin/tazobactam	R	2.8	6.3	3.5	6.4	7.1	13.9	15.9	20.6	8.9	10.2	0.5	0.9
Cefazolin	R	21.8	21.8	10.9	10.9			+	+	62.3	62.3	25.4	25.4
Cefoxitin	R	3.4	/	4.8	/			+	+	2.5	/	0.5	/
Ceftriaxone	NS	10.6	10.6	5.9	5.9			25.8	25.8	8.4	8.4	2.3	2.3
Ceftazidime	NS	6.1	9.9	4.9	6.9	10.4	10.4	22.4	24.2	1.3	2.1	1.4	1.8
Cefepime	NS	5.7	8.7	2.6	4.7	2.6	8.0	5.8	12.9	0.8	1.3	1.4	1.4
Meropenem	NS	<0.1	0.0	0.3	0.3	8.1	8.1	3.4	3.1	0.4	0.4	0.0	0.0
Ciprofloxacin	NS	12.6	13.6	3.9	7.2	6.3	6.5	3.4	4.0	0.4	0.4	4.1	4.5
Gentamicin	NS	7.8	7.9	4.2	4.5	2.4	3.4	6.7	7.4	0.8	1.3	0.5	1.8
Trimethoprim	R	31.0	31.3	15.4	16.1			16.0	16.0	3.4	3.4	18.1	19.0
Nitrofurantoin	R	1.3	1.3	32.4	/			20.6	/	2.1	/	+	+

*R = resistant, I = intermediate, NS = non-susceptible (intermediate + resistant), using criteria as published by the CLSI [2014] and EUCAST [2014].

†Considered largely intrinsically resistant due to natural β -lactamases; - no intermediate category; / no breakpoints defined

For EUCAST interpretation, clavulanate is fixed at 2 mg/L, rather than a 2:1 ratio used in CLSI guidelines. As all susceptibility test cards used have a 2:1 ratio of clavulanate, no EUCAST category has been applied.

Table 3. Number and proportion of acquired resistances (EUCAST) in Enterobacteriaceae, blood cultures, 2015

Number of acquired resistances (EUCAST breakpoints)																											
Species		Non-multidrug resistant						Cumulative%	Multidrug resistant												Cumulative%						
		0	1	2	3	4	5		6	7	8	9	10	11	12	13											
E. coli	Total	3,743	580	561	358	217	149	93	144	53	53	26	12	0	0	20.0%											
	%	40.0	15.5	15.0	9.6	5.8	4.0	2.5	3.8	1.4	1.4	0.7	0.3	0.0	0.0												
K. pneumoniae*	909	667	101	42	21	25	5	9	12	9	16	1	1			8.6%											
		73.4	11.1	4.6	2.3	2.8	0.6	1.0	1.3	1.0	1.8	0.1	0.1														
E. cloacae complex †	277	187	17	7	24	15	11	9	7	0	0	0				15.2%											
		67.5	6.1	2.5	8.7	5.4	4.0	3.2	2.5	0.0	0.0	0.0															
P. mirabilis	205	109	56	11	14	9	3	1	0	0	2	0	0	0		7.3%											
		53.2	27.3	5.4	6.8	4.4	1.5	0.5	0.0	0.0	1.0	0.7	0.0	0.0													
S. marcescens †	142	127	6	4	3	1	1	0	0	0	0	0				1.4%											
		89.4	4.2	2.8	2.1	0.7	0.7	0.0	0.0	0.0	0.0	0.0															
K. oxytoca*	217	72	111	4	12	15	2	0	1	0	0	0	0			8.3%											
		33.2	51.2	1.8	5.5	6.9	0.9	0.0	0.5	0.0	0.0	0.0	0.0														
E. aerogenes †	130	68	6	4	43	3	2	1	3	0	0	0				6.9%											
		52.3	4.6	3.1	33.1	2.3	1.5	0.8	2.3	0.0	0.0	0.0															
Salmonella spp. (non Typhi)	106	97	5	1	1	0	0	2	0	0	0	0	0	0		1.9%											
		91.5	4.7	0.9	0.9	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0												

* Antibiotics included: amoxycillin-clavulanate, piperacillin-tazobactam, cefazolin, cefixitin, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, nitrofurantoin, trimethoprim, meropenem; Antibiotics excluded: ampicillin (intrinsic resistance), ticarcillin-clavulanate, tobramycin, norfloxacin, nalidixic acid, sulfamethoxazole-trimethoprim, due to high correlation with antibiotics in the included list.

† Antibiotics included: piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, nitrofurantoin, trimethoprim, meropenem; Antibiotics excluded: ampicillin, amoxycillin-clavulanate, cefazolin, and cefixitin, (all four due to intrinsic resistance); also excluded were ticarcillin-clavulanate, tobramycin, norfloxacin, nalidixic acid, sulfamethoxazole-trimethoprim, due to high correlation with antibiotics in the included list.

producing strains, ciprofloxacin and gentamicin resistance was found in 60.7%/61.5% and 32.4%/32.4% respectively.

Most of the *E. coli* strains with ESBL genes harboured genes of the CTX-M type (349/408 = 86%). Over 65% of *E. coli* with CTX-M group 1 types were found to belong to sequence type 131 (O25b-ST131). ST131 accounted for 74% of *E. coli* ESBL phenotypes that were ciprofloxacin resistant (MIC >1 mg/L), and only 6% of ciprofloxacin susceptible ESBL phenotypes. Ninety-five percent and 64% of O25b-ST131 with an ESBL phenotype were associated with the H30 and H30-Rx subclones, respectively, consistent with their reported association with more antibiotic resistances and greater virulence potential.¹²

Klebsiella pneumoniae

K. pneumoniae showed slightly higher levels of resistance to piperacillin-tazobactam and ceftazidime compared with *E. coli*, but lower rates of resistance to amoxycillin-clavulanate, cefazolin, ceftriaxone, ciprofloxacin, gentamicin, and trimethoprim. Nine *K. pneumoniae* isolates had elevated meropenem MICs (see below). ESBLs were present in 53 of 71 (75%) presumptively ESBL-positive isolates of *K. pneumoniae*, 44 (83%) of which proved to be of the CTX-M type.

Enterobacter species

Acquired resistance was common to piperacillin-tazobactam (15.9%/20.6% and 27.7%/40.0%), ceftriaxone (25.8%/25.8% and 42.0%/42.0%), ceftazidime (22.4%/24.2% and 37.4%/39.7%) and trimethoprim (16.0%/16.0% and 6.2%/6.2%) for *E. cloacae* and *E. aerogenes*, respectively. Cefepime, ciprofloxacin, and gentamicin resistance were all less than 10%. Twenty-one *E. cloacae* strains had elevated meropenem MICs.

Carbapenemase resistance

Overall, 22 isolates (20 patients) in eleven institutions from five states/territories were found to harbour a carbapenemase gene. *bla*_{IMP-4} was detected in *E. cloacae* (8 isolates, from 7

patients), *Citrobacter freundii* (2), and in one *K. pneumoniae*, *K. oxytoca*, *Raoultella ornithinolytica* and *Serratia marcescens*; *bla*_{OXA-48} was detected in *K. pneumoniae* (4 isolates, from 3 patients); *bla*_{KPC} was detected in one *K. pneumoniae*; *bla*_{GES-5} was detected in one *P. aeruginosa*; *bla*_{NDM+OXA-48} was detected in one *K. pneumoniae*; and *bla*_{NDM-4+VIM-2} in one *P. aeruginosa*.

Discussion

AGAR has been tracking resistance in sentinel enteric Gram-negative bacteria since 1992. From 2008, surveillance was segregated into hospital versus community onset infections. The last year of hospital-onset only surveillance was 2011.¹⁴ In 2013, the first survey of antimicrobial resistance among Enterobacteriaceae isolates from bacteraemic patients through Australia was conducted using an approach similar to that conducted by the European Antimicrobial Resistance Surveillance Network (EARS-Net) program. 2015 was the third survey of antimicrobial resistance among Enterobacteriaceae, and the first to include *P. aeruginosa* and *Acinetobacter* spp. from bacteraemic patients through Australia.

CTX-M-producing *E. coli* and *Klebsiella* species and gentamicin- and ciprofloxacin-resistant *E. coli* continued to be a problem in patients with bacteraemia. Of concern is the high proportion of *E. coli* that belong to the ST131 H30-Rx subclone, and its recognised association with greater antibiotic resistance, in particular to ciprofloxacin, and greater virulence potential.¹² Carbapenem resistance attributable to acquired carbapenemases is still uncommon in patients with bacteraemia in Australia, although six different types of carbapenemase (IMP, KPC, NDM, OXA-48, VIM, and GES) were detected from eleven of the participating institutions. Compared with many other countries in our region, resistance rates in Australian Gram-negative bacteria are still relatively low¹⁵, but similar to those observed in 2015 in many Western European countries.²²

Multidrug resistance is being increasingly observed, especially in *E. coli* and *E. cloacae*,

both of which now have multidrug resistance rates (as defined by AGAR) above 15%. Despite national efforts to improve antimicrobial stewardship, increasing multi-resistance is likely to be a driver for broad-spectrum antibiotic use, and will increase the resistance selection pressure for important reserve classes, especially the carbapenemases.

Author Details

Ms Jan M Bell¹, A /Prof Thomas Gottlieb², Ms Denise A Daley³ and Prof Geoffrey W Coombs^{3,4}

1. University of Adelaide, Adelaide, South Australia, Australia
2. Concord Hospital, Concord, New South Wales
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Antimicrobial Resistance and Infectious Diseases Research Laboratory, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia
4. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Corresponding Author

A/Prof Thomas Gottlieb
Telephone: (02) 9767 7533

Email: thomas.gottlieb@health.nsw.gov.au

Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Health Care.

Members of the AGAR in 2015 were:

Australian Capital Territory

Peter Collignon and Susan Bradbury, The Canberra Hospital

New South Wales

Thomas Gottlieb and Graham Robertson, Concord Hospital

Rodney Givney and Ian Winney, John Hunter Hospital

James Branley and Donna Barbaro, Nepean Hospital

George Kotsiou and Peter Huntington, Royal North Shore Hospital

Sebastian van Hal and Bradley Watson, Royal Prince Alfred Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

Northern Territory

James McLeod, Alice Springs Hospital

Rob Baird and Jann Hennessy, Royal Darwin Hospital

Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology
Queensland Central Laboratory

Petra Derrington and Sharon Dal-Cin,
Pathology Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology
Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology
Queensland Princess Alexandra Hospital

Jenny Robson and Georgia Peachey, Sullivan
Nicolaides Pathology

South Australia

Kelly Papanoum and Nicholas Wells, SA
Pathology, Flinders Medical Centre

Morgyn Warner and Kija Smith, SA Pathology,
Royal Adelaide Hospital and Women's and
Children's Hospital

Tasmania

Louise Cooley and David Jones, Royal
Hobart Hospital

Victoria

Denis Spelman and Amanda Dennison, Alfred
Hospital

Paul Johnson and Peter Ward, Austin Hospital

Tony Korman and Despina Kotsanas, Southern
Health, Monash Medical Centre

Andrew Daley and Gena Gonis, Royal Women's
and Children's Hospital

Mary Jo Waters and Lisa Brenton, St Vincent's
Hospital

Western Australia

Shalini Perera and Ian Meyer,
Joondalup Hospital

David McGeachie and Denise Daley,
PathWest Laboratory Medicine WA,
Fiona Stanley Hospital

Ronan Murray and Jacinta Bowman, PathWest
Laboratory Medicine WA, Queen Elizabeth II
Medical Centre

Michael Leung, PathWest Laboratory Medicine
WA, remote WA

Owen Robinson and Geoffrey Coombs,
PathWest Laboratory Medicine WA,
Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler,
St John of God Pathology

References

1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Fifth Informational Supplement M100–S25. Villanova, PA, USA 2015.
2. European Committee on Antimicrobial Susceptibility Testing (2014). Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, January 2015. Available at http://www.eucast.org/clinical_breakpoints/. Accessed January 1, 2015.
3. Hanson ND, Thomson KS, Moland ES, Sanders CC, Berthold G, Penn RG. Molecular characterization of a multiply resistant *Klebsiella pneumoniae* encoding ESBLs and a plasmid-mediated AmpC. *J Antimicrob Chemother* 1999;44(3):377–380.
4. Chia JH, Chu C, Su LH, Chiu CH, Kuo AJ, Sun CF, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M β -lactamases of *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* in Taiwan. *J Clin Microbiol* 2005;43(9):4486–4491.

5. Birkett CI, Ludlam HA, Woodford N, Brown DFJ, Brown NM, Roberts MTM, et al. Real-time TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum β -lactamases. *J Med Microbiol* 2007;56(Pt 1):52–55.
6. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol* 2002;40(6):2153–2162.
7. Poirel L, H  ritier C, Tol  n V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2004;48(1):15–22.
8. Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, et al. Rapid detection and identification of metallo- β -lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *J Clin Microbiol* 2007;45(2):544–547.
9. Cattoir V, Poirel L, Rotimi V, Soussy C-J, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. *J Antimicrob Chemother* 2007;60:394–397.
10. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham DW. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. *J Med Microbiol* 2013;62:1823–1827.
11. Dhanjii H, Doumith M, Clermont O, Denamur E, Hope R, Livermore DM, et al. Real-time PCR for detection of the O25b-ST131 clone of *Escherichia coli* and its CTX-M-15-like extended-spectrum β -lactamases. *I J Antimicrob Agents* 2010;36:355–358.
12. Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, et al. Molecular Epidemiology of *Escherichia coli* Sequence Type 131 and Its H30 and H30-Rx Subclones among Extended-Spectrum- β -Lactamase-Positive and -Negative *E. coli* Clinical Isolates from the Chicago Region, 2007 to 2010. *Antimicrob Agents Chemother* 2013;57(12):6385–6388.
13. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, et al. *Escherichia coli* Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen Among US Veterans. *Clin Infect Dis* 2013;57(9):1256–65.
14. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J, for the Australian Group for Antimicrobial Resistance. Gram-negative Survey 2011 Antimicrobial Susceptibility Report. 2011 Adelaide. Available from: <http://www.agargroup.org/files/AGAR%20GNB08%20Report%20FINAL.pdf>
15. Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum β -lactamases, AmpC β -lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother* 2013;57(7):2981–2988.
16. <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/anti-microbial-resistanceeurope-2015.pdf>